Trial Profile
Study to Assess the Safety and Tolerability of Multiple Ascending Doses of REGN1500
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Jul 2019
Price :
$35
*
At a glance
- Drugs Evinacumab (Primary) ; Evinacumab (Primary)
- Indications Dyslipidaemias; Hypertriglyceridaemia
- Focus Adverse reactions
- Sponsors Regeneron Pharmaceuticals
- 27 Jun 2019 Results from two phase I studies of evinacumab (SAD and MAD studies) published in the Circulation
- 29 Sep 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
- 16 Mar 2015 Planned End Date changed from 1 Jun 2015 to 1 Sep 2015 as reported by ClinicalTrials.gov record.